STOCKS TELEGRAPH

Tag: Fulcrum Therapeutics

  • Rising Fortunes: Fulcrum Therapeutics (FULC) Is Surging Pre-Market

    Rising Fortunes: Fulcrum Therapeutics (FULC) Is Surging Pre-Market

    Fulcrum Therapeutics Inc.’s (NASDAQ: FULC) shares are witnessing a remarkable ascent on the US market today, reflecting a surge of 13.39% during the pre-market session, with a trading value of $8.47. This surge is attributed to a significant collaboration unveiling.

    Forward-Moving Cooperation

    For the development and commercialization of losmapimod, Fulcrum Therapeutics (FULC) has recently marked by a comprehensive collaboration and license agreement by collaborating with Sanofi. Losmapimod, an oral small molecule under investigation for treating facioscapulohumeral muscular dystrophy (FSHD), now stands as the focal point of this partnership. Sanofi secures exclusive commercialization rights for losmapimod outside the United States, marking a pivotal stride in advancing treatment modalities for FSHD patients globally.

    Exposing The Healing Potential

    Fulcrum Therapeutics’ extensive knowledge of FSHD is combined with Sanofi’s wide-ranging worldwide presence and steadfast dedication to the fight against rare illnesses in this partnership. Currently undergoing assessment in a global Phase 3 clinical trial for FSHD treatment, losmapimod targets a chronic and progressive genetic muscular disorder characterized by significant muscle cell deterioration and fat infiltration into muscle tissue.

    Encouraging results from the Phase 2 clinical trial, ReDUX4, showcased a deceleration in disease progression and enhanced muscle vitality. Fulcrum Therapeutics anticipates unveiling pivotal data from the REACH Phase 3 trial in the fourth quarter of 2024. Upon favorable outcomes, Fulcrum and Sanofi aim to pursue marketing applications across various territories including the United States, Europe, and Japan.

    Strategic Alignment And Financial Implications

    The partnership reflects Sanofi’s established prowess in developing therapeutics for rare neuromuscular conditions, positioning it as the ideal ally to amplify losmapimod’s potential beyond US borders. This synergistic endeavor aligns seamlessly with Fulcrum Therapeutics’ strategic blueprint, enabling the company to concentrate on readying losmapimod for commercialization in the US market while capitalizing on Sanofi’s exceptional global commercial capabilities and established foothold in key international markets.

  • Here’s why Fulcrum Therapeutics Inc. (FULC) performed well

    Fulcrum Therapeutics Inc. (FULC) recently presented new data and information regarding imaging biomarkers and clinical outcome assessments for facioscapulohumeral muscular dystrophy (FSHD). FULC stock closed $11.98 on 22nd March, increasing 5.46% compared to the $11.36 close last week on 19th March.

    Overview of Fulcrum Therapeutics, Inc.

    Fulcrum Therapeutics Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. Fulcrum has focused itself on making products that help in improving the lives of people that have genetically defined diseases, a medical area that is overlooked in the United States. The candidate products of Fulcrum are losmapimod and FTX-6058. Losmapimod is a small moleculein the second phase of a clinical trial for the cure and treatment of facioscapulohumeral muscular dystrophy. This rare muscle-wasting disorder leads to disability and significant physical impairments. The FTX-6058 is also a tiny molecule, but it is designed to upregulate fetal hemoglobin in patients with beta-thalassemia and sickle disease and is currently in phase-1 clinical development. Fulcrum was launched with a vision to revolutionize the course of genetically defined conditions by treating them at their root causes.

    Presentation of new data and information

    On 18th March 2021, Fulcrum Therapeutics Inc. presented new data and information regarding  imaging biomarkers and clinical outcome assessments for facioscapulohumeral muscular dystrophy (FSHD) at the online clinical and scientific conference of Muscular Dystrophy Association (MDA) 2021. The presentation included disease severity evaluation and the progression with WB-MSK-MRI (Whole Body Musculoskeletal Magnetic Resonance Imaging). AMRA medical and fulcrum have developed WB-MSK-MRI analysis algorithm and protocol to measure fat replacement of skeletal muscle in FSHD to use in multi-site clinical trials.

    FULC financial performance

    Fulcrum announced its fourth-quarter earnings on 3rd March 2021. Fulcrum reported a quarterly loss of $0.64 per share compared to the consensus estimate of a loss of $0.73. A year ago, Fulcrum reported a loss of $0.71 per share in the prior year. This quarterly report is a representation of an earnings surprise of 12.33%. It was expected that FULC would report a loss of $0.66 in the previous quarter, delivering a surprise of -6.06% and producing an actual loss of $0.70. Fulcrum has outperformed the market and has surpassed the consensus earnings per share in two of the last four quarters. Fulcrum has also reached the estimated revenue of 153.60% and reported $4.23 million for the fourth quarter. FULC stock closed $11.98 on 22nd March, increasing 5.46% compared to the $11.36 close last week on Friday.